Enhancement of bone formation in the setting of repeated tissue deformation.
The purpose of this study was to investigate whether the osteoinductive recombinant human bone morphogenetic protein 2, combined with a collagen carrier, could enhance bone formation when exposed to controlled amounts of tissue deformation. Chambers that allow for the multiple harvestings of tissue specimen were used. The devices were implanted in the tibial metaphyses of skeletally mature New Zealand White rabbits. A tissue ingrowth canal in each device either was left empty or filled with a collagen carrier with or without 0.6 microgram of recombinant human bone morphogenetic protein 2. The tissue ingrowth canal was deformed cyclically during a period of 2 minutes daily, according to a previously described deformation protocol. The tissue that developed in the chambers was harvested every 3 weeks. Undecalcified histologic sections of each tissue sample were stained with trichrome and von Kossa stains and subjected to histomorphometric analysis. It was found that deformation decreased the area occupied by bone trabeculae in the empty chambers and carrier controls. The amount of bone formed in the chambers treated with bone morphogenetic protein 2 was significantly greater than that in the chambers subjected to micromotion and left empty or implanted with the collagen carrier. The amount of bone in chambers with motion and bone morphogenetic protein 2 was equal to that in chambers left empty and not subjected to micromotion. Qualitative histologic analysis of the bone formed with bone morphogenetic protein 2 revealed normal bone trabeculae. These findings indicate that bone morphogenetic protein 2 may be useful in augmenting bone formation in conditions that otherwise would favor the formation of fibrous tissue.
Bostrom
M P
MP
Hospital for Special Surgery, New York, NY 10021, USA.
Aspenberg
P
P
Jeppsson
C
C
Salvati
E A
EA
D000818:Animals; D001273:Atmosphere Exposure Chambers; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D020007:Implants, Experimental; D008297:Male; D010012:Osteogenesis / Q000187:drug effects*; D011817:Rabbits; D051381:Rats; D011994:Recombinant Proteins; D013314:Stress, Mechanical; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
C525718:BMP2 protein, human; C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta